In children with mild cystic fibrosis (CF), daily doses of montelukast reduce markers of inflammation, according to the results of a randomized crossover trial. Dr. Sabina Schmitt-Groh and colleagues from the University of Bonn, Germany, randomly assigned 16 CF patients, 5 to 18 years of age, to montelukast or placebo once daily for 21 days.
After 21 days of treatment, patients crossed over to the alternate treatment for an additional 21 days following a 4-week washout period.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!